| Literature DB >> 17971868 |
Paolo Francesco Fabene1, Flavia Merigo, Mirco Galiè, Donatella Benati, Paolo Bernardi, Paolo Farace, Elena Nicolato, Pasquina Marzola, Andrea Sbarbati.
Abstract
The neuron loss characteristic of hippocampal sclerosis in temporal lobe epilepsy patients is thought to be the result of excitotoxic, rather than ischemic, injury. In this study, we assessed changes in vascular structure, gene expression, and the time course of neuronal degeneration in the cerebral cortex during the acute period after onset of pilocarpine-induced status epilepticus (SE). Immediately after 2 hr SE, the subgranular layers of somatosensory cortex exhibited a reduced vascular perfusion indicative of ischemia, whereas the immediately adjacent supragranular layers exhibited increased perfusion. Subgranular layers exhibited necrotic pathology, whereas the supergranular layers were characterized by a delayed (24 h after SE) degeneration apparently via programmed cell death. These results indicate that both excitotoxic and ischemic injuries occur during pilocarpine-induced SE. Both of these degenerative pathways, as well as the widespread and severe brain damage observed, should be considered when animal model-based data are compared to human pathology.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17971868 PMCID: PMC2040510 DOI: 10.1371/journal.pone.0001105
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Compared to controls (A), pilocarpine-treated animals 2 h post-SE onset (B) showed a specific laminar pattern in rCBV distribution, with increased values in the more superficial layers (white arrows) paralleled by a decrease in rCBV values in the deeper layers, indicating an ischemic area (gray arrows).
Figure 2Peak enhancement in control (A, C) and pilocarpine-treated animals (B, D).
Compared to controls, in rats during SE, sub-granular layers showed a decreased contrast medium peak concentration (D, blue dots), indicating a relative ischemic core, whereas supra-granular layers were characterized by hyperemia (D, red dots). Overlay rTTP maps on source images showing a generalized increase in blood flow rate in pilocarpine-treated (B) versus control brain (A). These alterations in the cerebral cortex of pilocarpine-treated rats present a specific spatial distribution (supra- (red arrow) versus sub-granular layers (blue arrow)).
Figure 3Vascular casts revealed structural alterations in brain vessels 2 h after SE-onset.
In the superficial, hyperperfused zone, veins were increased in diameter (B, E) whereas in the hypoperfused, edematous subgranular region, veins appeared collapsed (C, F).
Figure 4Agrin expression in control (A) and pilocarpine-treated (B) animals.
Increased agrin expression in the endothelial cells is evident in both superficial and deeper layers 2 h after SE-onset. This increase was more evident in the supergranular than in the subgranular layers. Localization of GFAP-like immunoreactivity revealed a selective increase in astrocytic GFAP expression in the less acutely damaged superficial layers (square).
Figure 5EM images in control animals and 2 h and 24 h after SE in both supergranular (A, A′, A″) and subgranular levels (B, B′, B″).
Subgranular layers are characterized of profound tissue damage 2 h after SE (B′) whereas supergranular layers at this time point appear to be normal except for the perivascular edema (A′). Twenty-four h after SE pathological evidences are detectable in both areas (A″′, B″′).
MicroArray analysis of cortical sample from supragranular vs subgranular layers at different time-points.
| 2 h | 24 h | |||
|
|
| |||
| Supragranular layers (II/III) | c- | FBJ murine osteosarcoma viral oncogene homolog | Apex 1 (689,5) | Apurinic/apyrimidinic endonuclease 1 |
| Ube 2d3 (2.85) | Ubiquitin-conjugating enzyme E2D 3 | Bax (2.0) (2.54) | Bcl-2associated X protein | |
| Ube 2i (2.0) | Ubiquitin-conjugating enzyme E2I | Cib 1 (86.8) | Calcium and integrin binding protein 1 | |
| TNF R sf1a (5.25) | Tumor necrosis factor receptor 1a | Becn1 (3.74) | Beclin 1 | |
| Cdkn2a (33.7) | Cyclin dependent kinase inhibitor 2a | Ube2i (2.7) | Ubiquitin-cojugating enzyme E2I | |
| Cdk 2 (2.1) | Cyclin dependent kinase 2 | Hspb1 (2.9) | Heat Shock 27 KDa Protein | |
| Hk2 (5.5) | Hexokinase 2 | Ctsd (2.5) | Cathepsin D | |
| Igf bp3 (2.09) | Insulin-like growth factor binding protein 3 | Fn1 (5.2) | Fibronectin 1 | |
| IL-4 R (2.2) | Interleukin 4 receptor | |||
| Ccl2 (7.5) | Chemokine (C-C motif)ligand 2 | |||
| a2m (9.0) | Alpha 2 microglobulin | |||
| bmp4 (5.7) | Bone morphogenetic protein 4 | |||
| Igfbp3 (2.26) | Insulin-like growth fact. bin prot 3 | |||
| Csn2 (4.6) | Casein beta | |||
| Cdk inhib 1b (4.7) | Cyclin dependent kinase inhibitor 1B | |||
| PCNA (3.09) | Proliferatine cell nuclear antigen | |||
| Ddit3 (2.97) | DNA-damage inducile transcript 3 | |||
| Smc11 (4.75) | Structural maintenance chromosomes | |||
| Ercc1 (5.8) | Similar to excision repair | |||
| Mre11a (3.0) | Meiotic recombination 11 homolog A | |||
| Mgmt (2.0) | O-6-metylguanine-DNA methyltransferase | |||
| Trex1 (4.8) | Similar to 3-5 exonuclease | |||
| Ercc3 (11.4) | Similar to TFII basal transcription factor complex helicase XPB subunit | |||
| Tdg (13.8) | Thymidine-DNA glycosilase | |||
| Atf2 (4.6) | Activating transcription factor 2 | |||
| Rad 23 a (0.5) | Similar to UV excision repair protein RAD23 homolog A | |||
| Pnkp (4.56) | Similar to polynucleotide kinase 3-phosphate | |||
|
|
| |||
| Hspb1 (0.48) | Heat shock 27 KDa protein | TNFsf13 (0.59) | Tumor necrosis factor ligand 13 | |
| Bax (0.36) | Bcl-2associated X protein | Birc1 (0.25) | Baculoviral IAP repeat-containing 1b | |
| Csf2 (0.48) | Colony stimulating factor 2 | C-fos (0.236) | FBJ murine osteosarcoma viral oncogene homolog | |
| Bmp4 (0.288) | Bone morphogenetic rotein 4 | Ei24 (0.42) | Similar to EI24 | |
| Csn2 (0.418) | Casein beta | |||
| Rad 23(0.22) | Similar to excision repair protein RAD23 homolog A | |||
| IL-2 (0.26) | Interleukin 2 | |||
| Hoxb1 (0.160) | ||||
|
|
| |||
| Subgranular layers (V/VI) | c- | Early growth response 1 | Ercc1 (2.0) | Similar to excision repair cross-complementing rodent repair deficiency, compl.group1 |
| V-Jun (3.7) | Rad23a (3.6) | Similar to UV excision repair protein RAD23 homolog A | ||
| NGF (2.0) | Nerve growth factor | Rad23b (8.0) | Similar to UV excision repair protein RAD23 homolog A | |
| TNFR1a (2.9) | Tumor necrosis factor receptor 1a | Cspg6 (7.45) | Caspase 6 | |
| Bcl 10 (16.4) | B-cell leukemia/lymphoma 10 | Cib 1 (4.8) | Calcium and integrin binding protein 1 | |
| Bcl 2 a 1 (5.6) | B-cell leucemia/lymphoma 2 related protein A1 | Dclre1a (4.5) | Similar to SNM1 protein | |
| PCNA (2.1) | Proliferatine cell nuclear antigen | Atrx (7.9) | Alpha thalassemia/mental retardation sindrome X-linked homolog (homolog) | |
| Xrcc1 (2.29) | x-ray repair complementing defective repair | Ddit 3 (7.7) | DNA-damage inducile transcript 3 | |
| Xrcc3 (2.29) | Similar to DNA-repair protein XRCC3 | Odc1 (3.8) | Ornithine decarboxylase 1 | |
| Csf2 (5.7) | Colony stimulating factor 2 | |||
| NGF (1.7) | Nerve growth factor | |||
| Bnip 3 (2.9) | BCL2/adenovirus E1B 19 KDa-interacting protein 1 | |||
| TNF R sf 1 a (2.4) | Tumor necrosis factor receptor 1A | |||
| DAP 3 (2.9) | ESTs, moderately similar to death associated protein 3 | |||
| Myd 88 (3.67) | Myeloid differentiation primary response gene 88 | |||
| Bcl2a1 (4.8) | B-cell leucemia/limphoma 2 related protein A1 | |||
| Bnip 1 (9.47) | BCL2/adenovirus E1B 19 kDa-interacting protein 1 | |||
| Becn 1 (2.9) | Beclin 1 | |||
| Hspb1 (3.0) | Heat shock 27 KDa protein | |||
|
|
| |||
| Bax (0.27) | Bcl-2associated X protein | c- | FBJ murine osteosarcoma viral oncogene homolog | |
| Bmp4 (0.13) | Bone morphogenetic protein 4 | Prkeb1 (0.43) | Protein kinase c beta 1 | |
| Egfr (0.3) | Epidhermal growth factor receptor | Cdkn2a (0.07) | Cyclin dependent kinase inhibitor 2° | |
| Bid3 (0.33) | BH3 interacting domain, apoptosis agonist | Bcl 10 (0.14) | B-cell CLL/lymphoma 10 | |
| TNFsf10 (79) | Tumor necrosis factor ligand 10 | |||